Intact Investment Management Inc. reduced its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 9.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,300 shares of the medical instruments supplier's stock after selling 1,800 shares during the quarter. Intact Investment Management Inc.'s holdings in Becton, Dickinson and Company were worth $3,963,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. REAP Financial Group LLC increased its position in shares of Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 55 shares in the last quarter. Picton Mahoney Asset Management grew its position in Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock valued at $32,000 after purchasing an additional 54 shares in the last quarter. Nexus Investment Management ULC purchased a new position in Becton, Dickinson and Company during the first quarter valued at approximately $34,000. Hopwood Financial Services Inc. purchased a new position in Becton, Dickinson and Company during the fourth quarter valued at approximately $39,000. Finally, Wood Tarver Financial Group LLC acquired a new stake in Becton, Dickinson and Company in the fourth quarter valued at approximately $49,000. 86.97% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of analysts have issued reports on BDX shares. The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 target price for the company. in a research note on Friday, May 2nd. William Blair cut shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 1st. Morgan Stanley reduced their price objective on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. Raymond James Financial cut shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Finally, Piper Sandler cut shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and cut their target price for the company from $260.00 to $185.00 in a research note on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $219.22.
View Our Latest Analysis on BDX
Becton, Dickinson and Company Price Performance
Shares of BDX traded up $1.30 during trading hours on Monday, hitting $169.72. The stock had a trading volume of 3,083,399 shares, compared to its average volume of 2,012,689. The company's fifty day moving average is $179.58 and its two-hundred day moving average is $211.12. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The stock has a market capitalization of $48.64 billion, a price-to-earnings ratio of 32.39, a P/E/G ratio of 1.27 and a beta of 0.25.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The business had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same quarter in the prior year, the firm earned $3.17 EPS. The firm's quarterly revenue was up 4.5% compared to the same quarter last year. On average, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.
Becton, Dickinson and Company Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.45%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio is currently 79.39%.
Insiders Place Their Bets
In related news, EVP David Shan sold 1,166 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the sale, the executive vice president now directly owns 4,575 shares in the company, valued at $783,194.25. This trade represents a 20.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael David Garrison sold 479 shares of the stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the sale, the executive vice president now owns 4,887 shares in the company, valued at $964,107.36. This represents a 8.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.36% of the company's stock.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
